Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
is known for its therapeutic benefit in various diseases including pain relief by targeting cannabinoid receptors. The primary component of cannabis, Δ9-tetrahydrocannabinol (THC), and other agonists engage the orthosteric site of CB1, activating both Gi and β-arrestin signaling pathways. The activation of diverse pathways could result in on-target side effects and cannabis addiction, which may hinder therapeutic potential. A significant challenge in pharmacology is the design of a ligand that can modulate specific signaling of CB1. By leveraging insights from the structure-function selectivity relationship (SFSR), we have identified Gi signaling-biased agonist-allosteric modulators (ago-BAMs). Further, two cryoelectron microscopy (cryo-EM) structures reveal the binding mode of ago-BAM at the extrahelical allosteric site of CB1. Combining mutagenesis and pharmacological studies, we elucidated the detailed mechanism of ago-BAM-mediated biased signaling. Notably, ago-BAM demonstrated analgesic efficacy with fewer side effects, minimal drug toxicity and no cannabis addiction in mouse pain models. In summary, our finding not only suggests that ago-BAMs of CB1 provide a potential nonopioid strategy for pain management but also sheds light on BAM identification for GPCRs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181136 | PMC |
| http://dx.doi.org/10.1073/pnas.2321532121 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
State of the Art Review: Thiazide diuretics exploit the endocannabinoid system via NAPE-PLD.
Am J Hypertens
September 2025
Laboratori ALIVEDA, Viale Karol Wojtyla 19, 56042 Crespina Lorenzana, Pisa, Italy.
The present State of the Art Review will take stock of targeting the endocannabinoid system (ECS) in the management of hypertension and vascular diseases. Major efforts have been made in the last thirty years to develop compounds modulating the ECS for diseases, both in the central and peripheral tissues. Agonists of the cannabinoid receptor CB1 elicited hypotension but were at strong risks of inducing tachycardia, heart and kidney damage.
View Article and Find Full Text PDFOrigin of the Different Binding Affinities of (9)- and (9)-Hexahydrocannabinol (HHC) for the CB and CB Cannabinoid Receptors.
ACS Chem Biol
August 2025
Department of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.
Hexahydrocannabinols (HHCs) are emerging cannabinoids that have become available for recreational use and were recently classified as Schedule II under an international treaty. Although often advertised for having desirable effects, recent studies have shown that commercial products typically contain variable amounts of two epimers, (9)-HHC and (9)-HHC. In turn, these epimers have been shown to have different binding affinities to the CB and CB receptors.
View Article and Find Full Text PDFHow THC works: Explaining ligand affinity for, and partial agonism of, cannabinoid receptor 1.
iScience
July 2025
Department of Chemistry and Biochemistry, University of Windsor, 401 Sunset Avenue, Windsor ON N9B 3P4, Canada.
Interaction with cannabinoid receptor 1 (CB1) partially determines the bioactivity of the phytocannabinoids. Consequently, there has also been significant effort directed toward preparing synthetic cannabinoids with either enhanced agonistic or antagonistic activity against this receptor. The design process of these molecules, and the identification of off-target effects at this receptor for molecules designed to target other proteins, would be aided by a reliable computational tool that can accurately predict binding.
View Article and Find Full Text PDFPharmacological characterization of a new synthesis compound with antagonistic action on CB1 receptors: Evidence from the animal experimental model.
Eur J Pharmacol
September 2025
Department of Health Promotion Sciences, Maternal and Child Care, Internal Medicine and Medical Specialties' Giuseppe D'Alessandro, University of Palermo, Via del Vespro 133, 90127, Palermo, Italy. Electronic address:
The endocannabinoid system is implicated in multiple physiological and pathological processes, making it a promising target for therapeutic intervention. CB1 receptor antagonists have shown potential in treating metabolic, neuropsychiatric, and addiction-related disorders. However, the adverse effects of CB1 antagonists like rimonabant have spurred the development of new compounds with improved safety profiles.
View Article and Find Full Text PDFColchicine-BODIPY Probes: Evidence for the Involvement of Intracellular Membranes in the Targeting of Colchicine to Tubulin.
ACS Pharmacol Transl Sci
July 2025
Institute of Molecular and Translational Medicine (IMTM), Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Hněvotínská 1333/5, Olomouc CZ-779 00, Czech Republic.
The natural product colchicine () is a medication used to treat severe inflammatory conditions. Although its mechanism of action at the level of the cytoskeleton is known, its subcellular distribution has not yet been properly studied. In this work, we present the first rational approach to assess the intracellular localization and biological activity of this alkaloid.
View Article and Find Full Text PDF